Although anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) drugs have achieved considerable clinical efficacy and low toxicity, they are not effective in all cancer types or do not achieve the desired effect in all patients (33). Here, CD274 is linked to cancer.